Related Experiment Video
Updated: Aug 19, 2025

A Method to Define the Effects of Environmental Enrichment on Colon Microbiome Biodiversity in a Mouse Colon Tumor Model
Published on: February 28, 2018
Gut Microbiota Eubacterium callanderi Exerts Anti-Colorectal Cancer Activity
Seoung Woo Ryu1, Ji-Sun Kim1, Byeong Seob Oh1
1Korean Collection for Type Cultures, Biological Resource Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, Republic of Korea.
Abstract:
The gut microbiota (GM) is associated with colorectal cancer (CRC) development. However, studies demonstrating the role of GM in CRC are limited to metagenomic analyses. These studies lack direct evidence proving that the candidate strains are involved in CRC, and isolated probiotics for bacteriotherapy. Therefore, to identify novel GM with anti-CRC activity, we previously isolated gut bacteria from the feces of healthy individuals, screened the isolated GM's anti-CRC activity, and discovered that cell-free supernatants of GM isolates demonstrated antiproliferative activity against CRC cells. Here, our study identified one of them as Eubacterium callanderi and chose it for further study because the genus Eubacterium has been suggested to contribute to various aspects of gut health; however, the functions are unknown. First, we confirmed that E. callanderi cell-free supernatant (EcCFS) exerted antiproliferative activity-by inducing apoptosis and cell cycle arrest-that was dose-dependent and specific to cancer cell lines. Next, we discovered that EcCFS active molecules were heat stable and protease insensitive. High-performance liquid chromatography analysis revealed that EcCFS contained high butyrate concentrations possessing anticancer activity. Additionally, gas chromatography-mass spectrometry analysis of the aqueous phase of ethyl acetate-extracted EcCFS and an antiproliferation assay of the aqueous phase and 4-aminobutanoic acid (GABA) suggested that GABA is a possible anti-CRC agent. Finally, in the CT26 allograft mouse model, E. callanderi oral administration and EcCFS peri-tumoral injection inhibited tumor growth in vivo. Therefore, our study reveals that E. callanderi has an anti-CRC effect and suggests that it may be a potential candidate for developing probiotics to control CRC. IMPORTANCE The gut microbiota has been reported to be involved in colorectal cancer, as suggested by metagenomic analysis. However, metagenomic analysis has limitations, such as bias in the analysis and the absence of bacterial resources for follow-up studies. Therefore, we attempted to discover gut microorganisms that are related to colorectal cancer using the culturomics method. In this study, we discovered that Eubacterium callanderi possesses anti-colorectal cancer activity in vitro and in vivo, suggesting that E. callanderi could be used in bacteriotherapy for colorectal cancer treatment.
Insights
Eubacterium callanderi shows anti-colorectal cancer (CRC) activity. This gut bacterium, through its cell-free supernatant, inhibits CRC cell proliferation and tumor growth in mice, suggesting potential for probiotic bacteriotherapy.
Area of Science:
- Microbiology
- Oncology
- Gastroenterology
Background:
- Gut microbiota (GM) is linked to colorectal cancer (CRC) development.
- Metagenomic studies provide indirect evidence, lacking direct bacterial strain validation.
- Limited understanding of specific GM strains' roles in CRC pathogenesis and therapeutic potential.
Purpose of the Study:
- To identify novel gut bacteria with anti-CRC activity using culturomics.
- To investigate the anti-CRC effects of Eubacterium callanderi and its active compounds.
- To evaluate E. callanderi's potential for CRC bacteriotherapy.
Main Methods:
- Isolation and screening of gut bacteria for anti-CRC activity.
- Analysis of E. callanderi cell-free supernatant (EcCFS) for antiproliferative effects.
- Biochemical analysis (HPLC, GC-MS) to identify active molecules (butyrate, GABA).
- In vivo studies using a CT26 allograft mouse model.
Main Results:
- EcCFS demonstrated dose-dependent, cancer cell-specific antiproliferative activity via apoptosis and cell cycle arrest.
- Active molecules in EcCFS were heat-stable and protease-insensitive.
- High concentrations of butyrate and 4-aminobutanoic acid (GABA) were identified as potential anti-CRC agents.
- Oral administration of E. callanderi and EcCFS injection inhibited tumor growth in mice.
Conclusions:
- Eubacterium callanderi exhibits significant anti-CRC activity both in vitro and in vivo.
- The study identifies butyrate and GABA as key anti-CRC compounds produced by E. callanderi.
- E. callanderi represents a promising candidate for developing novel probiotic-based bacteriotherapies for colorectal cancer.
More Related Videos
06:07Evaluating Cell Death Using Cell-Free Supernatant of Probiotics in Three-Dimensional Spheroid Cultures of Colorectal Cancer Cells
Published on: June 13, 2020
06:24Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023